ATE337011T1 - Modifizierte psma-liganden und deren verwendung - Google Patents
Modifizierte psma-liganden und deren verwendungInfo
- Publication number
- ATE337011T1 ATE337011T1 AT02761082T AT02761082T ATE337011T1 AT E337011 T1 ATE337011 T1 AT E337011T1 AT 02761082 T AT02761082 T AT 02761082T AT 02761082 T AT02761082 T AT 02761082T AT E337011 T1 ATE337011 T1 AT E337011T1
- Authority
- AT
- Austria
- Prior art keywords
- psma ligands
- modified psma
- diagnosis
- detection
- treatment
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/005—Compounds of elements of Group 5 of the Periodic Table without metal-carbon linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/301—Acyclic saturated acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
- C07F9/32—Esters thereof
- C07F9/3205—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/3211—Esters of acyclic saturated acids which can have further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6596—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having atoms other than oxygen, sulfur, selenium, tellurium, nitrogen or phosphorus as ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/66—Arsenic compounds
- C07F9/70—Organo-arsenic compounds
- C07F9/72—Aliphatic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/24—Condensed ring systems having three or more rings
- C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26705501P | 2001-02-07 | 2001-02-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE337011T1 true ATE337011T1 (de) | 2006-09-15 |
Family
ID=23017130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02761082T ATE337011T1 (de) | 2001-02-07 | 2002-02-07 | Modifizierte psma-liganden und deren verwendung |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US6875886B2 (de) |
| EP (1) | EP1363920B1 (de) |
| JP (1) | JP2005507857A (de) |
| AT (1) | ATE337011T1 (de) |
| CA (1) | CA2436408A1 (de) |
| DE (1) | DE60214134T2 (de) |
| MX (1) | MXPA03007037A (de) |
| WO (1) | WO2002098885A1 (de) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7468354B2 (en) | 2000-12-01 | 2008-12-23 | Genspera, Inc. | Tissue specific prodrugs |
| ES2314272T3 (es) * | 2003-01-10 | 2009-03-16 | Millennium Pharmaceuticals, Inc. | Metodos para el diagnostico y el tratamiento del cancer. |
| WO2007001448A2 (en) | 2004-11-04 | 2007-01-04 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
| EP1841467A4 (de) * | 2005-01-14 | 2009-01-28 | Cytogen Corp | Kombinationskrebstherapie mit anti-psma-antikörpern |
| US7811572B2 (en) | 2005-08-24 | 2010-10-12 | Immunogen, Inc. | Process for preparing purified drug conjugates |
| US20060264414A1 (en) * | 2005-04-08 | 2006-11-23 | The Board of Regents, University and Community College System of Nevada on behalf of the | Fluorous 2,2'-bipyridines and fluorinated biphasic sysems for ligand design |
| AU2006235421A1 (en) * | 2005-04-08 | 2006-10-19 | Cytogen Corporation | Conjugated anti-PSMA antibodies |
| WO2006121920A2 (en) * | 2005-05-05 | 2006-11-16 | Beth Israel Deaconess Medical Center, Inc. | Micro-scale resonant devices and methods of use |
| CA2626435A1 (en) * | 2005-10-18 | 2007-05-10 | Centre National De La Recherche Scientifique (Cnrs) | Hypophosphorous acid derivatives and their therapeutical applications |
| US9267937B2 (en) | 2005-12-15 | 2016-02-23 | Massachusetts Institute Of Technology | System for screening particles |
| PL1999136T3 (pl) * | 2006-03-14 | 2013-03-29 | Cancer Targeted Tech Llc | Peptydomimetyczne inhibitory PSMA, związki je zawierające i sposoby ich zastosowania |
| WO2008105773A2 (en) | 2006-03-31 | 2008-09-04 | Massachusetts Institute Of Technology | System for targeted delivery of therapeutic agents |
| WO2007150030A2 (en) * | 2006-06-23 | 2007-12-27 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
| US7993927B2 (en) | 2006-07-03 | 2011-08-09 | Beth Israel Deaconess Medical Center, Inc. | Histology methods |
| US20100144845A1 (en) * | 2006-08-04 | 2010-06-10 | Massachusetts Institute Of Technology | Oligonucleotide systems for targeted intracellular delivery |
| US20110033379A1 (en) * | 2006-08-29 | 2011-02-10 | Frangioni John V | Radio-labeled materials and methods of making and using the same |
| JP2010509570A (ja) * | 2006-11-03 | 2010-03-25 | パーデュー・リサーチ・ファウンデーション | エクスビボフローサイトメトリーの方法および装置 |
| US9217129B2 (en) | 2007-02-09 | 2015-12-22 | Massachusetts Institute Of Technology | Oscillating cell culture bioreactor |
| US20090074828A1 (en) * | 2007-04-04 | 2009-03-19 | Massachusetts Institute Of Technology | Poly(amino acid) targeting moieties |
| WO2009002529A2 (en) | 2007-06-26 | 2008-12-31 | The Johns Hopkins University | Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents |
| EP2183258A2 (de) * | 2007-08-01 | 2010-05-12 | Centre National de la Recherche Scientifique (CNRS) | Thiophosphi(o)nsäurederivate und deren verwendung als agonisten oder antagonisten für metabotrope glutamatrezeptoren |
| DK2187965T3 (da) | 2007-08-17 | 2020-01-20 | Purdue Research Foundation | Psma-bindingsligand-linker-konjugater og fremgangsmåder til anvendelse |
| FR2920086A1 (fr) | 2007-08-24 | 2009-02-27 | Univ Grenoble 1 | Systeme et procede d'analyse pour une operation chirurgicale par endoscopie |
| ATE530169T1 (de) | 2007-09-28 | 2011-11-15 | Bind Biosciences Inc | Krebszellen-targeting mit nanopartikeln |
| MX2010003642A (es) | 2007-10-12 | 2010-08-09 | Massachusetts Inst Technology | Nanotecnologia de vacuna. |
| EA020753B1 (ru) | 2008-06-16 | 2015-01-30 | Бинд Терапьютикс, Инк. | Терапевтические полимерные наночастицы, содержащие алкалоиды vinca, и их применение |
| AU2009268923B2 (en) | 2008-06-16 | 2015-09-17 | Pfizer Inc. | Drug loaded polymeric nanoparticles and methods of making and using same |
| WO2010005726A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences Inc. | Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same |
| US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
| US8591905B2 (en) | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
| US20110288152A1 (en) * | 2008-10-17 | 2011-11-24 | Purdue Research Foundation | Psma binding ligand-linker conjugates and methods for using |
| WO2010068866A2 (en) | 2008-12-12 | 2010-06-17 | Bind Biosciences | Therapeutic particles suitable for parenteral administration and methods of making and using same |
| EA201100765A1 (ru) * | 2008-12-15 | 2012-04-30 | Бинд Биосаиэнсис | Наночастицы длительной циркуляции для замедленного высвобождения терапевтических средств |
| US10493169B2 (en) | 2009-02-06 | 2019-12-03 | Beth Israel Deaconess Medical Center | Use of charge-balanced imaging agents for determining renal function |
| SG2014009146A (en) | 2009-02-06 | 2014-05-29 | Beth Israel Hospital | Charge-balanced imaging agents |
| CA2769444A1 (en) | 2009-05-19 | 2010-11-25 | Aic Blab Company | Composite current collector and methods therefor |
| JP5784592B2 (ja) | 2009-06-03 | 2015-09-24 | イミュノジェン・インコーポレーテッド | 抱合方法 |
| CN102811743B (zh) | 2009-12-11 | 2015-11-25 | 佰恩德治疗股份有限公司 | 冻干治疗颗粒的稳定制剂 |
| JP5965844B2 (ja) | 2009-12-15 | 2016-08-10 | バインド セラピューティックス インコーポレイテッド | 高いガラス転移温度または高分子量のコポリマーを有する治療用ポリマーナノ粒子組成物 |
| US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
| EA033468B1 (ru) | 2011-03-29 | 2019-10-31 | Immunogen Inc | Способы получения конъюгата "антитело-майтансиноид" |
| EP3064945A1 (de) * | 2012-02-24 | 2016-09-07 | Cornell University | Erhöhter psma-wert als identifikator von tödlichem prostatakrebs |
| CA2865774A1 (en) * | 2012-02-28 | 2013-09-06 | Cornell University | Psma as a biomarker for androgen activity in prostate cancer |
| HUE043998T2 (hu) | 2012-09-17 | 2019-09-30 | Pfizer | Eljárás terápiás nanorészecskék elõállítására |
| EP2904089A4 (de) | 2012-10-04 | 2016-05-25 | Immunogen Inc | Verwendung einer pvdf-membran zur reinigung von konjugaten aus zellbindendem mittel und zytotoxikum |
| KR102318999B1 (ko) | 2012-11-15 | 2021-10-29 | 엔도사이트, 인코포레이티드 | Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트 |
| MX358184B (es) | 2013-03-15 | 2018-08-08 | Purdue Research Foundation | Sintesis y composicion de grupos de enlace de aminoacidos conjugados con compuestos usados para la toma de imagenes dirigida de tumores. |
| US20170232119A1 (en) | 2013-03-15 | 2017-08-17 | Purdue Research Foundation | Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors |
| EP2842578B1 (de) * | 2013-08-27 | 2018-06-27 | GILUPI GmbH | Diagnosevorrichtung zum nachweis von biomarkern |
| AU2014336638C1 (en) | 2013-10-18 | 2020-09-17 | Novartis Ag | Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| WO2015073678A1 (en) | 2013-11-14 | 2015-05-21 | Endocyte, Inc. | Compounds for positron emission tomography |
| EP3116547B1 (de) | 2014-03-14 | 2019-06-05 | Pfizer Inc | Therapeutische nanopartikel mit einem behandlungsmittel sowie verfahren zur herstellung und verwendung davon |
| JP2017530109A (ja) * | 2014-09-08 | 2017-10-12 | モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド | 前立腺癌についてのpsmaを標的とした放射性核種治療中の臓器の保護 |
| US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
| MX2020010813A (es) | 2018-04-17 | 2021-01-08 | Endocyte Inc | Metodos de tratamiento de cancer. |
| EP3972627A4 (de) | 2019-05-20 | 2023-06-21 | Endocyte, Inc. | Verfahren zur herstellung von psma-konjugaten |
| DE102019215585B4 (de) * | 2019-10-10 | 2022-02-17 | KCM Egészségügyi és Tudományos Korlátolt Felelösségü Társaság | Verfahren zur prävention von strahlenschäden in humanen drüsen |
| WO2022106629A1 (en) | 2020-11-19 | 2022-05-27 | Novartis Ag | Synthesis of prostate specific membrane antigen (psma) ligands |
| JP2024532521A (ja) | 2021-09-03 | 2024-09-05 | 晶核生物医藥科技(南京)有限公司 | ペプチド-尿素誘導体、それを含む医薬組成物、及びそれらの使用 |
| IL319722A (en) | 2022-09-23 | 2025-05-01 | Nuclidium Ag | High purity radionuclides and their diagnostic and medical uses |
| TW202426433A (zh) | 2022-09-23 | 2024-07-01 | 瑞士商紐利迪姆股份公司 | 成纖維細胞活化蛋白(fap)抑制劑、fap結合物及其診斷與治療用途 |
| WO2025167998A1 (zh) * | 2024-02-06 | 2025-08-14 | 北京昌平实验室 | 膦酸酯骨架的psma靶向偶联物 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1757695A3 (de) | 1992-11-05 | 2008-02-27 | Sloan Kettering Institute For Cancer Research | Prostata-spezifisches Membranantigen |
| US5804602A (en) * | 1996-06-17 | 1998-09-08 | Guilford Pharmaceuticals Inc. | Methods of cancer treatment using naaladase inhibitors |
| US6384022B1 (en) * | 1996-06-17 | 2002-05-07 | Guilford Pharmaceuticals Inc. | Prodrugs of NAALAdase inhibitors |
| JP2002515040A (ja) | 1996-06-17 | 2002-05-21 | ギルフォード・ファーマシューティカルズ・インコーポレイテッド | Naaladアーゼ阻害剤を用いる癌治療方法 |
| US6025344A (en) | 1996-06-17 | 2000-02-15 | Guilford Pharmaceuticals Inc. | Certain dioic acid derivatives useful as NAALADase inhibitors |
| US6054444A (en) | 1997-04-24 | 2000-04-25 | Guilford Pharmaceuticals Inc. | Phosphonic acid derivatives |
| US6046180A (en) | 1996-06-17 | 2000-04-04 | Guilford Pharmaceuticals Inc. | NAALADase inhibitors |
| US5902817A (en) | 1997-04-09 | 1999-05-11 | Guilford Pharmaceuticals Inc. | Certain sulfoxide and sulfone derivatives |
| US6071965A (en) * | 1996-06-17 | 2000-06-06 | Guilford Pharmaceuticals Inc. | Phosphinic alkanoic acid derivatives |
| US6025345A (en) | 1996-06-17 | 2000-02-15 | Guilford Pharmaceuticals Inc. | Inhibitors of NAALADase enzyme activity |
| US5962521A (en) | 1997-04-04 | 1999-10-05 | Guilford Pharmaceuticals Inc. | Hydroxamic acid derivatives |
| WO1998013046A1 (en) | 1996-09-27 | 1998-04-02 | Guilford Pharmaceuticals Inc. | Naaladase compositions and methods for treating glutamate abnormality and effecting neuronal activity in animals |
| US5981209A (en) | 1997-12-04 | 1999-11-09 | Guilford Pharmaceuticals Inc. | Use of NAALADase activity to identify prostate cancer and benign prostatic hyperplasia |
| US6444657B1 (en) * | 1998-12-31 | 2002-09-03 | Guilford Pharmaceuticals Inc. | Methods for treating certain diseases using naaladase inhibitors |
| US6348464B1 (en) | 1999-11-12 | 2002-02-19 | Guilford Pharmaceuticals, Inc. | Pyrrolecarbonylimino derivatives as naaladase inhibitors |
| US7254409B2 (en) * | 2000-04-14 | 2007-08-07 | Ntt Docomo, Inc. | Multicast service providing system, multicast service providing method, information distributor, radio terminal, and radio base station |
| AU2001265111A1 (en) | 2000-05-30 | 2001-12-11 | Guilford Pharmaceuticals Inc. | Benzenedicarboxylic acid derivatives |
| US6594498B1 (en) * | 2000-08-14 | 2003-07-15 | Vesuvius, Inc. | Communique system for cellular communication networks |
| US6684076B2 (en) * | 2000-08-14 | 2004-01-27 | Vesuvius Inc. | Communique system with hierarchical communique coverage areas in cellular communication networks |
| US6954641B2 (en) * | 2000-08-14 | 2005-10-11 | Vesivius, Inc. | Communique wireless subscriber device for a cellular communication network |
| US7024200B2 (en) * | 2000-08-14 | 2006-04-04 | Vesuvius, Inc. | Communique system with active feedback for cellular communication networks |
| US6741856B2 (en) * | 2000-08-14 | 2004-05-25 | Vesuvius Inc. | Communique system for virtual private narrowcasts in cellular communication networks |
| US6681115B1 (en) * | 2000-08-14 | 2004-01-20 | Vesuvius Inc. | Communique subscriber handoff between a narrowcast cellular communication network and a point-to-point cellular communication network |
| US6829486B2 (en) * | 2000-08-14 | 2004-12-07 | Vesuvius | Communique system for combined cellular and wireline communication networks |
| US6687498B2 (en) * | 2000-08-14 | 2004-02-03 | Vesuvius Inc. | Communique system with noncontiguous communique coverage areas in cellular communication networks |
| US6907023B2 (en) * | 2000-08-14 | 2005-06-14 | Vesuvius, Inc. | Communique system with dynamic bandwidth allocation in cellular communication networks |
| EP1341557A2 (de) * | 2000-10-27 | 2003-09-10 | Beth Israel Deaconess Medical Center | Nichtisotopischer nachweis von osteoblastischer aktivität in vivo mittels modifizierten bisphosphonaten |
| MXPA03006467A (es) | 2001-01-17 | 2004-01-29 | Guilford Pharm Inc | Inibidores de naaladasa a base de tiol. |
-
2002
- 2002-02-07 CA CA002436408A patent/CA2436408A1/en not_active Abandoned
- 2002-02-07 AT AT02761082T patent/ATE337011T1/de not_active IP Right Cessation
- 2002-02-07 MX MXPA03007037A patent/MXPA03007037A/es unknown
- 2002-02-07 DE DE60214134T patent/DE60214134T2/de not_active Expired - Fee Related
- 2002-02-07 WO PCT/US2002/021996 patent/WO2002098885A1/en not_active Ceased
- 2002-02-07 EP EP02761082A patent/EP1363920B1/de not_active Expired - Lifetime
- 2002-02-07 US US10/071,890 patent/US6875886B2/en not_active Expired - Lifetime
- 2002-02-07 JP JP2003502006A patent/JP2005507857A/ja active Pending
-
2004
- 2004-06-16 US US10/869,790 patent/US20040229845A1/en not_active Abandoned
-
2005
- 2005-07-01 US US11/173,055 patent/US20050245486A1/en not_active Abandoned
-
2007
- 2007-07-19 US US11/880,124 patent/US20080175789A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1363920A1 (de) | 2003-11-26 |
| DE60214134D1 (de) | 2006-10-05 |
| US6875886B2 (en) | 2005-04-05 |
| EP1363920A4 (de) | 2004-04-21 |
| JP2005507857A (ja) | 2005-03-24 |
| MXPA03007037A (es) | 2003-11-18 |
| US20040110723A1 (en) | 2004-06-10 |
| EP1363920B1 (de) | 2006-08-23 |
| DE60214134T2 (de) | 2007-07-19 |
| US20040229845A1 (en) | 2004-11-18 |
| US20050245486A1 (en) | 2005-11-03 |
| US20080175789A1 (en) | 2008-07-24 |
| WO2002098885A1 (en) | 2002-12-12 |
| CA2436408A1 (en) | 2002-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60214134D1 (de) | Modifizierte psma-liganden und deren verwendung | |
| WO2004067570A3 (en) | Prostate cancer diagnosis and treatment | |
| BR0111125A (pt) | Moléculas de ácido nucléico de nrg-2, polipeptìdeos, e métodos diagnóstico e terapêuticos | |
| WO1998035693A3 (en) | Detection and modulation of the iaps and naip for the diagnosis and treatment of proliferative disease | |
| MXPA04006517A (es) | Conjugados que comprenden un anticuerpo especifico para el dominio ed-b de fibronectina y sus usos para la deteccion y tratamiento de tumores. | |
| EP1362124A4 (de) | Verfahren und sonden für den nachweis von krebs | |
| DE69936049D1 (de) | Monoklonale antikörper spezifisch für die extrazelluläre domäne des prostata-spezifischen membranantigens | |
| PH12021552960A1 (en) | Claudin-6 binding molecules and uses thereof | |
| ATE424560T1 (de) | Marker für neuromyelitis optica | |
| DE69507470D1 (de) | Diagnose von krebs, dessen zellen das am tyrosin phosphorylierte crkl-protein exprimieren | |
| ATE317451T1 (de) | Verfahren zur diagnose, erkennung, und einstufung von dickdarmkrebs | |
| ATE352311T1 (de) | Verwendung von brustkrebs membranproteine für behandlung, prophylaxe und diagnose von brustkrebs | |
| DE602004028819D1 (de) | Teilchendetektor geeignet für die erkennung von ionen und elektronen | |
| DE60109430D1 (de) | An entzündlichen darmerkrankungen beteiligte gene und deren verwendung | |
| WO2004016160A3 (en) | Redox polymer nanoparticles | |
| DE60032784D1 (de) | Markerproteine für prostatakrebs | |
| WO2003093794A3 (en) | Methods for discovering tumor biomarkers and diagnosing tumors | |
| IL139852A0 (en) | Monoclonal antibodies directed against the g3bp protein, and uses | |
| DE50205750D1 (de) | Liganden für den nachweis von prionen | |
| MXPA05007940A (es) | Composiciones y metodos para el tratamiento del cancer usando igsf9 y liv-1. | |
| DE60335610D1 (de) | Neoplasma-spezifische antikörper und deren verwendungen | |
| WO2004101762A3 (en) | Detection and treatment of cancers of the colon | |
| WO2003002765A3 (en) | Methods for the diagnosis of cancer based on the obcam and ntm genes | |
| NO20004250L (no) | Humaniserte anti-TAG-72 monoklonale antistoffer med høy affinitet | |
| WO2003024302A3 (en) | Detection and treatment of cancers of breast |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |